IGHE and nasal cavity polyp: Lastly, omalizumab, a humanized monoclonal antibody directed against free circulating IgE preventing its binding with the high-affinity IgE receptor FcεRI, in two phase 3 clinical trials (POLYP 1 and POLYP 2), significantly improved endoscopic, clinical, and patient-reported symptoms in adult patients with bilateral nasal polyps with weight and serum IgE levels permitting omalizumab dosing [160].